Kamada (NASDAQ:KMDA – Get Free Report) was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a report released on Thursday.
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price target on shares of Kamada in a research note on Thursday, March 6th.
Check Out Our Latest Stock Analysis on KMDA
Kamada Stock Down 0.7 %
Hedge Funds Weigh In On Kamada
A number of hedge funds have recently modified their holdings of the stock. NewEdge Advisors LLC increased its stake in shares of Kamada by 54.2% in the fourth quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock worth $143,000 after acquiring an additional 8,260 shares during the last quarter. Aristides Capital LLC increased its position in Kamada by 12.1% during the fourth quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company’s stock worth $387,000 after buying an additional 6,850 shares during the last quarter. Geode Capital Management LLC increased its position in Kamada by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock worth $178,000 after buying an additional 1,549 shares during the last quarter. JPMorgan Chase & Co. acquired a new position in Kamada during the fourth quarter worth $67,000. Finally, Public Employees Retirement System of Ohio acquired a new position in Kamada during the third quarter worth $77,000. 20.38% of the stock is owned by institutional investors and hedge funds.
About Kamada
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.
Further Reading
- Five stocks we like better than Kamada
- Insider Trades May Not Tell You What You Think
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- Comparing and Trading High PE Ratio Stocks
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.